Immutep

sLAG-3

Immutep S.A. announced today the publication of a research paper showing that soluble LAG-3 (Lymphocyte Activation Gene-3) protein (sLAG-3) is a prognostic indicator for survival in breast cancers expressing oestrogen or progesterone receptors. The results pave the way for the testing of a recombinant sLAG-3 protein as an adjuvant therapy for breast cancer in clinical trials.

The study (Cancer Letters 235 (2006) 147-153) was carried out by Dr Marie-France Pichon and Kamel Hacene of the René Huguenin Cancer Centre in Saint-Cloud, near Paris, and Pr. Frédéric Triebel when he was at the Pharmacy Faculty of University Paris 11. Dr Triebel is now Scientific and Medical Director of Immutep S.A.

Click to read the complete Press Release (PDF Format).


Published 04/2006 by admin@immutep.com